Retatrutide and Fatty Liver: The MASH Breakthrough

What Is Fatty Liver Disease? MASLD and MASH Explained

Fatty liver disease has undergone a significant naming overhaul in the past two years. What was previously called NAFLD (non-alcoholic fatty liver disease) is now known as MASLD — metabolic dysfunction-associated steatotic liver disease. The more severe, inflammatory stage formerly called NASH (non-alcoholic steatohepatitis) is now MASH — metabolic dysfunction-associated steatohepatitis.

The name changes reflect a better understanding of the disease. The old names defined the condition by what it was not (non-alcoholic), whereas the new terminology identifies what actually drives it: metabolic dysfunction — insulin resistance, obesity, type 2 diabetes, and related metabolic conditions.

Here is how the disease progresses:

1. MASLD (steatosis): Excess fat accumulates in the liver (more than 5% of liver weight). Often symptomless. Reversible with lifestyle changes.
2. MASH (steatohepatitis): Fat accumulation triggers chronic inflammation and liver cell damage. Liver enzymes rise. Still potentially reversible, but the window is narrowing.
3. Fibrosis: Scar tissue forms in the liver as a response to ongoing inflammation. Staged from F1 (mild) to F4 (cirrhosis). Partially reversible in early stages.
4. Cirrhosis: Extensive, irreversible scarring that can lead to liver failure or hepatocellular carcinoma (liver cancer).

The prevalence numbers are striking. Fatty liver disease affects approximately 1 in 5 people in the UK, and globally, MASLD now affects an estimated 38% of the adult population — making it the most common chronic liver disease worldwide. Among people with type 2 diabetes, the picture is even worse: roughly two out of three have some degree of liver steatosis.

The insidious aspect of fatty liver disease is that it is largely silent. Most people with MASLD have no symptoms whatsoever. The liver does not have pain receptors in the same way that other organs do, so fat can accumulate and inflammation can progress for years — even decades — before anything is noticed. By the time symptoms like fatigue, abdominal discomfort, or jaundice appear, the disease is often advanced.

This is precisely why blood testing for liver function markers matters — it is the most accessible way to detect liver damage before it becomes irreversible.

The Retatrutide Liver Breakthrough

In June 2024, researchers led by Arun J. Sanyal published the results of a Phase 2a liver sub-study in Nature Medicine — and the data was extraordinary.

The study enrolled 98 participants with obesity and elevated liver fat. They were randomly assigned to receive once-weekly subcutaneous injections of retatrutide (at doses of 1, 4, 8, or 12 mg) or placebo for 48 weeks. Liver fat was measured using MRI-proton density fat fraction (MRI-PDFF), which is the gold-standard imaging technique for quantifying hepatic steatosis.

Liver Fat Reduction: Dose-by-Dose Results

Let those numbers sink in. At the highest dose, retatrutide eliminated 86% of liver fat over 48 weeks — and 93% of participants achieved completely normal liver fat levels. Zero participants on placebo achieved normalisation.

Even at the lowest 1 mg dose, more than half of participants had normal liver fat by 48 weeks. And the data shows that most of the reduction happened in the first 24 weeks, with continued improvement to week 48 — suggesting that the liver responds rapidly to the drug's mechanisms.

To put this in context, these are the most dramatic liver fat reduction results ever published for any drug in clinical development. They surpass what has been achieved with semaglutide, tirzepatide, or resmetirom (Rezdiffra) — the only drugs currently approved or in advanced trials for MASH.

Why Retatrutide Works for Fatty Liver: The Glucagon Mechanism

The critical question is: why does retatrutide work so dramatically well for fatty liver, when other GLP-1-based drugs also reduce liver fat but to a lesser degree?

The answer lies in retatrutide's third receptor target — the glucagon receptor.

Retatrutide is a triple-hormone-receptor agonist that simultaneously activates three receptor types:

• GLP-1 receptors — reduce appetite, slow gastric emptying, improve insulin sensitivity
• GIP receptors — amplify insulin response, enhance fat metabolism
• Glucagon receptors — stimulate hepatic fatty acid oxidation, increase energy expenditure, reduce lipogenesis

All three pathways contribute to liver fat reduction indirectly through weight loss and improved insulin sensitivity. But the glucagon component adds two direct, liver-specific mechanisms that the other pathways lack:

1. Hepatic Fatty Acid Oxidation

When glucagon receptors in the liver are activated, hepatocytes (liver cells) ramp up fatty acid oxidation — essentially, the liver switches from storing fat to burning it. This is a direct, weight-independent effect: the liver burns its own stored fat regardless of how much weight the person has lost overall.

The clinical evidence for this mechanism is measurable. In the Phase 2a trial, participants on retatrutide doses of 4 mg and above showed a two- to threefold increase in beta-hydroxybutyrate, a ketone body that is produced when the liver oxidises fatty acids. This is a direct biomarker of hepatic fat burning.

Crucially, the largest increases in beta-hydroxybutyrate occurred by week 24 — the same timepoint at which most of the liver fat reduction had already occurred. The correlation between beta-hydroxybutyrate levels and liver fat changes was statistically significant, confirming that glucagon-driven fatty acid oxidation is a primary driver of the liver fat reduction seen with retatrutide.

2. Reduced Hepatic Lipogenesis

In addition to burning existing fat, glucagon receptor activation reduces the liver's production of new fat (de novo lipogenesis). In MASLD, the liver is overproducing fat due to insulin resistance and excess caloric intake. Retatrutide's glucagon pathway helps shut down this overproduction at the source.

This dual action — burn more stored fat, produce less new fat — is why retatrutide's liver fat results are so dramatically superior to drugs that rely only on weight loss and insulin sensitisation. Semaglutide and tirzepatide reduce liver fat primarily through indirect mechanisms (weight loss, improved insulin resistance). Retatrutide does all of that plus directly reprogramming the liver's fat metabolism through glucagon signalling.

It also explains the dose-response pattern in the data. At 1 mg, the glucagon component is relatively modest, and the liver fat reduction (−51.3% at 48 weeks) is driven largely by weight loss and insulin improvement. At 8 and 12 mg, the glucagon signal becomes strong enough to produce the dramatic >80% reductions that distinguish retatrutide from everything else in the MASH pipeline.

How Retatrutide Compares to Other MASH Treatments

The MASH treatment landscape has transformed rapidly. Until March 2024, there were zero approved drugs for fatty liver disease. Now, two drugs have received FDA approval, and several others (including retatrutide) are in advanced trials. Here is how they compare.

A few important caveats when reading this comparison:

• Different endpoints: The ESSENCE and SYNERGY-NASH trials used liver biopsies to assess MASH resolution and fibrosis improvement. The retatrutide Phase 2a study used MRI-PDFF to measure liver fat content. These are different (but complementary) measures. Retatrutide's Phase 3 MASLD trial will likely use biopsy endpoints, giving a direct comparison.
• Different trial stages: Resmetirom and semaglutide have Phase 3 data in large populations. Tirzepatide has Phase 2 data. Retatrutide's liver data comes from a Phase 2a sub-study of 98 participants. Larger Phase 3 data will be essential for confirmation.
• MASH resolution vs liver fat reduction: Reducing liver fat is necessary but not sufficient. What matters clinically is whether inflammation resolves and fibrosis improves or stabilises. Retatrutide's Phase 2a study was not powered to assess these histological outcomes.

That said, the sheer magnitude of retatrutide's liver fat reduction — 86% at the highest dose — is unprecedented. And the glucagon-mediated mechanism gives reason to believe that the inflammation and fibrosis improvements will follow in Phase 3 data.

The UK Treatment Landscape

As of early 2026, the MASH treatment landscape in the UK remains limited. Resmetirom (Rezdiffra) received EU approval in 2025 but is not yet routinely available through the NHS (NICE appraisal is pending). Semaglutide received FDA approval for MASH in August 2025, but a specific MASH indication from the MHRA has not yet been confirmed. In practice, UK patients with fatty liver disease are primarily managed through lifestyle interventions — weight loss, dietary changes, and exercise — with limited pharmacological options.

This gap makes early detection through blood testing even more important. If you identify fatty liver disease early, lifestyle interventions can be remarkably effective. If you wait until symptoms appear, the options narrow significantly.

Detecting Fatty Liver with Blood Tests

You cannot feel fatty liver disease. But you can detect it — and the first-line screening tools are simple blood tests that any GP or at-home testing service can provide.

Key Liver Biomarkers

ALT (alanine transaminase) is the most specific blood marker for liver cell damage. When liver cells are inflamed or injured — as they are in MASH — they release ALT into the bloodstream. A persistently elevated ALT (above 33 U/L for men, 25 U/L for women, using updated guidelines) should prompt further investigation for fatty liver disease. However, ALT can be normal even in the presence of significant liver fat, which is why it should not be used alone.

AST (aspartate transaminase) is another liver enzyme, though it is less liver-specific than ALT (it is also found in heart, muscle, and other tissues). The AST-to-ALT ratio provides additional diagnostic value: a ratio above 1.0 can suggest more advanced fibrosis, whereas a ratio below 1.0 is more typical of early MASLD.

GGT (gamma-glutamyl transferase) is often the earliest liver enzyme to become elevated in fatty liver disease. It is particularly sensitive to hepatic steatosis and biliary stress. An elevated GGT in someone who is overweight or has metabolic syndrome should raise suspicion for MASLD even if ALT and AST are within normal range.

ALP (alkaline phosphatase) is a marker of cholestatic (bile duct-related) liver disease rather than hepatocellular damage. It is less useful for MASLD screening but is typically included in a comprehensive liver function panel and helps distinguish between different types of liver pathology.

The FIB-4 Score: Screening for Fibrosis

The FIB-4 Index is a non-invasive fibrosis screening tool that combines four routine measurements into a single score:

Interpreting the result:

The FIB-4 score is recommended by both the American Association of Clinical Endocrinology and NHS guidelines as the preferred initial screening tool for liver fibrosis in people at risk of fatty liver disease. You can calculate it yourself using age, AST, ALT, and platelet count from a standard blood test.

Low platelet counts deserve special attention. The liver plays a role in platelet production, and when it becomes fibrotic, platelets can become trapped in the organ. A declining platelet count — even within the normal range — can be an early signal of advancing liver disease.

Blood Tests to Monitor Liver Health

Whether you are concerned about fatty liver disease, monitoring the effects of a weight loss medication, or simply tracking your metabolic health over time, the right blood test panel gives you objective data that symptoms alone cannot provide.

For liver health monitoring, you need a panel that includes:

• Full liver function: ALT, AST, GGT, ALP, albumin, bilirubin
• Metabolic markers: HbA1c, fasting glucose, fasting insulin (to assess insulin resistance, the primary driver of MASLD)
• Lipid panel: Total cholesterol, LDL, HDL, triglycerides (fatty liver disease and dyslipidaemia are tightly linked)
• Full blood count: Including platelet count (for FIB-4 calculation)
• Inflammatory markers: CRP or hsCRP (chronic inflammation is the hallmark of MASH)

Both the Core Health 45 (45 biomarkers) and Peak Insights 70 (70 biomarkers) include the full liver function panel, metabolic markers, lipids, full blood count, and inflammatory markers needed to screen for fatty liver disease and calculate your FIB-4 score. Peak Insights 70 adds additional markers including iron studies, thyroid function, and vitamin levels — particularly relevant if you are also tracking the effects of weight loss medications or dietary changes.

Importantly, you do not need a GP referral to get these tests. Lola Health's at-home venous blood tests are collected by a qualified phlebotomist at your home and processed in a UKAS-accredited laboratory. Results are typically available within 2–4 working days, with clear reference ranges and personalised insight into what your numbers mean.

If you have risk factors for fatty liver disease — overweight or obesity, type 2 diabetes, metabolic syndrome, high triglycerides, or a family history of liver disease — testing at least once a year is a sensible baseline. If your results show elevated liver enzymes, more frequent monitoring (every 3–6 months) is advisable to track whether interventions are working.

Frequently Asked Questions

References and Sources

1. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30:2037–2048. Nature Medicine
2. Loomba R, Hartman ML, Engel SS, et al. AASLD 2023: Retatrutide resolves steatosis in >85% of subjects with MASLD and obesity. AASLD
3. Newsome PN, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis (ESSENCE). N Engl J Med. 2025. NEJM
4. Lilly. Tirzepatide for MASH with liver fibrosis (SYNERGY-NASH). N Engl J Med. 2024. NEJM
5. Harrison SA, et al. A Phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis (MAESTRO-NASH). N Engl J Med. 2024;390:497–509. NEJM
6. Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs. December 2025. Eli Lilly Press Release
7. British Liver Trust. MASLD, NAFLD and fatty liver disease. British Liver Trust
8. Sterling RK, et al. Fibrosis-4 (FIB-4) Index for Liver Fibrosis. MDCalc